Coagulation Factor X Proteine (F10)

F10 encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. Zusätzlich bieten wir Ihnen Coagulation Factor X Antikörper (250) und Coagulation Factor X Kits (68) und viele weitere Produktgruppen zu diesem Protein an.

alle Proteine anzeigen Gen GeneID UniProt
F10 2159 P00742
F10 14058 O88947
F10 29243 Q63207
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen

Top Coagulation Factor X Proteine auf

Showing 10 out of 33 products:

Katalog Nr. Origin Quelle Konjugat Bilder Menge Anbieter Lieferzeit Preis Details
Insektenzellen Human His tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 1 mg Anmelden zum Anzeigen 50 Days
Insektenzellen Maus His tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 1 mg Anmelden zum Anzeigen 50 Days
Escherichia coli (E. coli) Human His tag,T7 tag 50 μg Anmelden zum Anzeigen 13 bis 16 Tage
Baculovirus infected Insect Cells Human His tag 10 μg Anmelden zum Anzeigen 14 bis 16 Tage
Human Cells Maus His tag   50 μg Anmelden zum Anzeigen 4 Days
HEK-293 Cells Human Myc-DYKDDDDK Tag Validation with Western Blot 20 μg Anmelden zum Anzeigen Verfügbar
Human Cells Human Fc Tag   50 μg Anmelden zum Anzeigen 4 Days
Wheat germ Human GST tag 10 μg Anmelden zum Anzeigen 11 bis 12 Tage
Human Cells Human Fc Tag   10 μg Anmelden zum Anzeigen 15 bis 16 Tage
Human Human Unkonjugiert   400 μg Anmelden zum Anzeigen 2 bis 3 Tage

F10 Proteine nach Spezies und Herkunft

Origin Exprimiert in Konjugat
Human , , , , , ,
, , , ,
Mouse (Murine) , , , ,
Rat (Rattus) , ,

Weitere Proteine zu Coagulation Factor X (F10) Interaktionspartnern

Human Coagulation Factor X (F10) Interaktionspartner

  1. model predicts that small vesicles promote activation of FX by the extrinsic tenase significantly better than large vesicles

  2. miR-24 was overexpressed in major trauma-induced coagulopathy (TIC) patients. The negative correlation of miR-24 with FX suggested the possibility that miR-24 might inhibit the synthesis of FX during TIC.

  3. this study demonstrated that thrombin and factor Xa cleavage sites on HEV pORF1 are obligatory for HEV replication.

  4. zymogen-like factor Xa variants are conformationally dynamic and ligands such as its cofactor, factor Va, stabilize the molecule rescuing procoagulant activity. At the site of vascular injury, the variants in the presence of factor Va serve as effective prohemostatic agents.

  5. Data suggest that, for all coagulation proteins tested (prothrombin, factor X, activated factor VII, activated protein C), tighter binding to lipid bilayers (lower Kd) is observed as the proportion of anionic phospholipid increases. These studies were conducted in high-throughput screening using phospholipid bilayers in nanodiscs with multiplexed silicon photonic sensor (micro-ring resonator) array technology.

  6. A coagulation initiating pathway is revealed in which the TF-FVIIa-nascent FXa complex activates FVIII apart from thrombin feedback.

  7. Data suggest oxidized lipid vesicles with phosphatidylserine/polyunsaturated fatty acids promote inactivation of ZPI-PZ complex or free ZPI; binding of PZ-complexed or free ZPI to oxidized vesicles mediates inactivation of ZPI (an inhibitor of FXa); blocking heparin- (anticoagulant-)binding site on ZPI interferes with binding to lipid or PZ. (ZPI = protein Z-dependent protease inhibitor; PZ = protein Z; FXa = factor Xa)

  8. Factor Va reduced by 100-fold the apparent Kd of myosin for factor Xa (Kd approximately 0.48 nM), primarily by reducing koff, indicating formation of a stable ternary complex of myosin:Xa:Va.

  9. PTX2 was identified PTX2 as a novel partner for FX, and both proteins cooperated to prevent their SR-AI-mediated uptake by macrophages.

  10. annexin A2 contributes to lung injury and fibrotic disease by mediating the fibrogenic actions of FXa.

  11. Individuals suffering from relapsing-remitting and secondary progressive multiple sclerosis had significantly higher prothrombin and factor X levels than healthy donors, whereas levels were unchanged in primary progressive MS and neuromyelitis optica patients.

  12. Low concentrations of TF and exogenous FXIa, each too low to elicit a burst in thrombin production alone, act synergistically when in combination to cause substantial thrombin production.

  13. A family with factor X deficiency from Argentina displayed a compound heterozygous proband having the combination of a new mutation with an already known one, and homozygous children.

  14. analysis of how physiological concentrations of Tissue factor pathway inhibitor inhibit FXa

  15. According to our study, compounds 1a, 1g and 1s displayed evident FXa inhibitory activity and excellent selectivity over thrombin in in vitro inhibition activities studies.

  16. This study was conducted to assess the spectrum of factor X gene mutation in Iranian patients with congenital factor X deficiency (FXD). Most molecular studies found a diversity in factor X disease causing mutations in Iranian patients. Like other parts of the world, the majority of mutations in Iranian patients were missense mutations, but splice-site mutations were relatively common. [review]

  17. Large deletions play a minor but essential role in the mutational spectrum of the F7 and F10 genes. Copy number analyses (e. g. MLPA) should be considered if sequencing cannot clarify the underlying reason of an observed coagulopathy. Of note, in cases of combined FVII/FX deficiency, a deletion of the two contiguous genes might be part of a larger chromosomal rearrangement.

  18. The Ala275Val substitution is a pathogenic mutation that causes the inherited FX deficiency.

  19. homozygous mutation g.27881G>A(p.Val298Met) of the F10 gene has been identified, which probably accounts for the low FX concentrations in this pedigree

  20. Establish FXa as a potentially important asthma mediator, stimulating airway smooth muscle function through actions requiring PAR-1 and annexin A2 and involving integrin coactivation.

Mouse (Murine) Coagulation Factor X (F10) Interaktionspartner

  1. PTX2 was identified PTX2 as a novel partner for FX, and both proteins cooperated to prevent their SR-AI-mediated uptake by macrophages.

  2. annexin A2 contributes to lung injury and fibrotic disease by mediating the fibrogenic actions of FXa.

  3. Enhanced FXa and PAR2 exacerbate DN and that both are promising targets for preventing diabetic nephropathy.

  4. Macrophages regulate FX plasma levels in an SR-AI-dependent manner.

  5. Factor Xa has a role in inhibiting HMGB1-induced septic responses in human umbilical vein endothelial cells and in mice

  6. Selective inhibition of FXa improves the left ventricular function during CVB3-induced myocarditis and seems to be associated with an improved myocardial remodeling.

  7. Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells.

  8. Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate.

  9. There was no detectable increase in plasma levels of mouse FX after active-site inhibited human APC administration to mice overexpressing human EPCR. FX does not effectively interact with EPCR in vivo, at least in regards to the mouse system.

  10. investigation of role of F10a in progression of diabetic nephropathy: data from studies using inhibitor of F10a suggest that F10a does play a role in development of proteinemia, glomerular hypertrophy, and protein deposition in kidney of db/db mice

  11. Data suggest that tissue factor and factor V induction by LPS may in part accelerate mesangioproliferative glomerulonephritis through activation of factor X and downstream proinflammatory and procoagulant mechanisms.

  12. Gene targeting of tissue factor, factor X, and factor VII in mice: their involvement in embryonic development

  13. Factor Xa functions in airway remodeling in asthma by stimulating mucin production, through regulation of amphiregulin expression and collagen deposition.

  14. Complete absence of FX is incompatible with murine survival. Minimal FX activity as low as 1-3% is sufficient to rescue the lethal phenotype.

  15. Results show that although factor Xa induces p42/44 MAP Kinase phosphorylation in endothelial cells, it has no direct effect on endothelial cell proliferation, protein synthesis and tube formation.

  16. expression of coagulation factor X (FX) is locally increased in fibrotic lung tissue, with marked immunostaining associated with bronchial and alveolar epithelia

Cow (Bovine) Coagulation Factor X (F10) Interaktionspartner

  1. Identify potential phosphatidylserine-specific binding sites in the membrane binding domain of coagulation factor X.

  2. Data suggest factor Xa (FXa) and factor Va (FVa) compete to bind FXa on both PS model membranes and microparticles from activated platelets; this competition between dimerization/prothrombinase complex formation appears to regulate blood coagulation.

  3. thrombin and factor Xa diffusion along the heparin molecule explains the effects of extended heparin chain lengths

  4. Factor Xa (fXa), a key serine protease of the coagulation system, was used as a model enzyme to test the canonical conformation hypothesis.

Zebrafish Coagulation Factor X (F10) Interaktionspartner

  1. These findings as well as the prolonged survival of f10(-/-) mutants will enable us to expand our understanding of the molecular mechanisms of hemostasis, including a platform for screening variants of uncertain significance in patients with F10 deficiency and other coagulation disorders

Coagulation Factor X (F10) Protein Überblick

Protein Überblick

This gene encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. This factor undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds\; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity.

Genbezeichner und Symbole assoziert mit Coagulation Factor X Proteine (F10)

  • coagulation factor X (F10)
  • coagulation factor X (f10)
  • coagulation factor X (CpipJ_CPIJ012712)
  • coagulation factor X (CpipJ_CPIJ014863)
  • coagulation factor X (CpipJ_CPIJ016937)
  • coagulation factor X (CpipJ_CPIJ017791)
  • Coagulation factor X (fa10)
  • coagulation factor 10 L homeolog (f10.L)
  • Cf10 Protein
  • f10 Protein
  • fi12c10 Protein
  • fX Protein
  • FXA Protein
  • wu:fi12c10 Protein

Bezeichner auf Proteinebene für Coagulation Factor X Proteine (F10)

Stuart-Prower factor , factor Xa , prothrombinase , stuart factor , coagulation factor 10 , VAP , factor XA light chain , virus activating protease , virus-activating protease , coagulation factor X , vitamin K dependent serine protease , coagulation factor X preproprotein , blood coagulation factor X , Coagulation factor X , coagulation factor 10 L homeolog

2159 Homo sapiens
14058 Mus musculus
29243 Rattus norvegicus
280787 Bos taurus
282670 Danio rerio
395876 Gallus gallus
445942 Takifugu rubripes
452679 Pan troglodytes
476993 Canis lupus familiaris
714132 Macaca mulatta
790961 Ornithorhynchus anatinus
6045845 Culex quinquefasciatus
6048453 Culex quinquefasciatus
6050511 Culex quinquefasciatus
6052088 Culex quinquefasciatus
100008647 Oryctolagus cuniculus
100022394 Monodelphis domestica
100137443 Papio anubis
100380501 Salmo salar
100408094 Callithrix jacchus
100453258 Pongo abelii
100471482 Ailuropoda melanoleuca
100607918 Nomascus leucogenys
100726878 Cavia porcellus
101118624 Ovis aries
398778 Xenopus laevis
Ausgewählte Anbieter für Coagulation Factor X Proteine (F10)
Haben Sie etwas anderes gesucht?